Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

6.100 +0.260 (+4.45%)
Delayed Quote Updated: 10:47 AM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday! 
Via InvestorPlace
News headline image
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets ↗
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
News headline image
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More ↗
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
News headline image
SciSparc And Clearmind Reveal Three Unique Combinations Of Future Psychedelic-Based Compounds ↗
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its... 
Via Benzinga
News headline image
Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US ↗
Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications... 
Via Benzinga
News headline image
EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead ↗
(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction 
Via Benzinga
News headline image
Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results ↗
Israeli-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained... 
Via Benzinga
News headline image
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More ↗
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday! 
Via InvestorPlace
News headline image
EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When ↗
(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction 
Via Benzinga
News headline image
EXCLUSIVE: Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains ↗
(This is part two of a four-part series) Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction 
Via Benzinga
News headline image
Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction ↗
(Part one of a four-part series) Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to... 
Via Benzinga
News headline image
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects ↗
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem. 
Via Benzinga
News headline image
Envisioning A Cocaine-Addiction Treatment: This Next-Gen Psychedelic Shows Positive Results ↗
Israel-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) shared additional positive results on the impact of the MEAI molecule in the natural reward process in an in-vivo preclinical... 
Via Benzinga
News headline image
This Original Psychedelic-Based Obesity Treatment Set To First-In-Human Trials ↗
Psychedelics biopharma company Clearmind Medicine Inc. (NASDAQ: CMND) and clinical-stage firm SciSparc Ltd. 
Via Benzinga
News headline image
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways ↗
What a year for psychedelics! 
Via Benzinga
News headline image
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More ↗
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
News headline image
Israeli Psychedelics Biotech Shares Latest Advancements, Moves Forward With Addictions Treatment ↗
Psychedelics company Clearmind Medicine Inc. (NASDAQ: CMND) aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for... 
Via Benzinga
News headline image
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! 
Via InvestorPlace
News headline image
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More ↗
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon 
Via Benzinga
News headline image
Clearmind Gears Up For Clinical Trial To Test Drug That Treats Alcohol Addiction ↗
Israeli psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) is commencing the production of its proprietary drug candidate based on the MEAI molecule. 
Via Benzinga
News headline image
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More ↗
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
News headline image
This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split ↗
Psychedelics biotech firm Clearmind Medicine Inc. 
Via Benzinga
News headline image
Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.